Literature DB >> 6275121

Expression of Epstein-Barr viral early antigen in monolayer tissue cultures after transfection with viral DNA and DNA fragments.

E Grogan, G Miller, W Henle, M Rabson, D Shedd, J C Niederman.   

Abstract

Antigens associated with the Epstein-Barr virus (EBV) replicative cycle were found in the nucleus and cytoplasm of human placental, Vero, BSC-1, and owl monkey kidney cells transfected with EBV DNA prepared from several different strains of virus. The number of antigen-positive nuclei increased when transfection was followed by cell fusion induced by inactivated Sendai virus. About 1,200 antigen-positive foci were induced per micrograms of EBV DNA. On the basis of their reactivity with various well-characterized human sera, it appears that the antigens are part of the early antigen complex. None of the four restriction endonucleases, EcoRI, HindIII, SalI, and BamHI, destroyed the ability of EBV DNA to induce early antigen. However, only SalI seemed to leave intact the full spectrum of antigen expression by the HR-1 and FF41 strains of EBV DNA. By means of transfection with recombinant DNA plasmids containing different EBV (FF41) DNA fragments regenerated by EcoRI, we showed that the coding region for early antigen was at least partially contained on the 17.2-megadalton EcoRI B fragment.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6275121      PMCID: PMC256697     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  22 in total

1.  Demonstration of two distinct components in the early antigen complex of Epstein-Barr virus-infected cells.

Authors:  G Henle; W Henle; G Klein
Journal:  Int J Cancer       Date:  1971-09-15       Impact factor: 7.396

2.  Trypsinized placental cell cultures for the propagation of viruses and as "feeder layers".

Authors:  E A Grogan; J F Enders; G Miller
Journal:  J Virol       Date:  1970-03       Impact factor: 5.103

3.  Poliovirus replication and cytopathogenicity in monolayer hamster cell cultures fused with beta propiolactone-inactivated Sendai virus.

Authors:  J M Neff; J F Enders
Journal:  Proc Soc Exp Biol Med       Date:  1968-01

4.  Epstein-Barr virus RNA. VI. Viral RNA in restringently and abortively infected Raji cells.

Authors:  W King; V Van Santen; E Kieff
Journal:  J Virol       Date:  1981-05       Impact factor: 5.103

5.  Monoclonal antibodies against the major glycoprotein (gp350/220) of Epstein-Barr virus neutralize infectivity.

Authors:  D A Thorley-Lawson; K Geilinger
Journal:  Proc Natl Acad Sci U S A       Date:  1980-09       Impact factor: 11.205

6.  Transformation induced by Epstein-Barr virus and the role of the nuclear antigen.

Authors:  G Klein; J Luka; J Zeuthen
Journal:  Cold Spring Harb Symp Quant Biol       Date:  1980

7.  Epstein-Barr viral DNA: infectivity for human placental cells.

Authors:  G Miller; E Grogan; L Heston; J Robinson; D Smith
Journal:  Science       Date:  1981-04-24       Impact factor: 47.728

8.  Expression of Epstein-Barr virus genes in different cell types after microinjection of viral DNA.

Authors:  A Graessmann; H Wolf; G W Bornkamm
Journal:  Proc Natl Acad Sci U S A       Date:  1980-01       Impact factor: 11.205

9.  Transfer of Epstein-Barr virus receptors to receptor-negative cells permits virus penetration and antigen expression.

Authors:  D J Volsky; I M Shapiro; G Klein
Journal:  Proc Natl Acad Sci U S A       Date:  1980-09       Impact factor: 11.205

10.  Genome of a mononucleosis Epstein-Barr virus contains DNA fragments previously regarded to be unique to Burkitt's lymphoma isolates.

Authors:  D K Fischer; G Miller; L Gradoville; L Heston; M W Westrate; W Maris; J Wright; J Brandsma; W C Summers
Journal:  Cell       Date:  1981-05       Impact factor: 41.582

View more
  14 in total

1.  Epstein-Barr viral DNA in tissues of Hodgkin's disease.

Authors:  L M Weiss; J G Strickler; R A Warnke; D T Purtilo; J Sklar
Journal:  Am J Pathol       Date:  1987-10       Impact factor: 4.307

2.  The analysis of EBV proteins which are antigenic in vivo.

Authors:  D Walls; M Perricaudet; F Gannon
Journal:  Nucleic Acids Res       Date:  1988-04-11       Impact factor: 16.971

3.  Mapping of polypeptides encoded by the Epstein-Barr virus genome in productive infection.

Authors:  M Hummel; E Kieff
Journal:  Proc Natl Acad Sci U S A       Date:  1982-09       Impact factor: 11.205

4.  Two Epstein-Barr viral nuclear neoantigens distinguished by gene transfer, serology, and chromosome binding.

Authors:  E A Grogan; W P Summers; S Dowling; D Shedd; L Gradoville; G Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1983-12       Impact factor: 11.205

5.  Expression in COS-1 cells of Epstein-Barr virus nuclear antigen from a complete gene and a deleted gene.

Authors:  M F Robert; D Shedd; R J Weigel; D K Fischer; G Miller
Journal:  J Virol       Date:  1984-06       Impact factor: 5.103

6.  Rescue of transforming Epstein-Barr virus (EBV) from EBV-genome-positive epithelial hybrid cells transfected with subgenomic fragments of EBV DNA.

Authors:  J Stoerker; R Glaser
Journal:  Proc Natl Acad Sci U S A       Date:  1983-03       Impact factor: 11.205

Review 7.  Epstein-Barr virus (EBV), lymphocytes and transformation.

Authors:  J Zeuthen
Journal:  J Cancer Res Clin Oncol       Date:  1983       Impact factor: 4.553

8.  Expression of a nuclear and a cytoplasmic Epstein-Barr virus early antigen after DNA transfer: cooperation of two distant parts of the genome for expression of the cytoplasmic antigen.

Authors:  K Takaki; A Polack; G W Bornkamm
Journal:  Proc Natl Acad Sci U S A       Date:  1984-07       Impact factor: 11.205

9.  Stable expression in mouse cells of nuclear neoantigen after transfer of a 3.4-megadalton cloned fragment of Epstein-Barr virus DNA.

Authors:  W P Summers; E A Grogan; D Shedd; M Robert; C R Liu; G Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1982-09       Impact factor: 11.205

10.  Non-immortalizing P3J-HR-1 Epstein-Barr virus: a deletion mutant of its transforming parent, Jijoye.

Authors:  M Rabson; L Gradoville; L Heston; G Miller
Journal:  J Virol       Date:  1982-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.